In-Stent Carotid Artery RestenosisCERCASNCT05390983
Carotid Endarterectomy vs. Repeated Carotid Angioplasty and Stenting for In-Stent Restenosis
A study testing Carotid endarterectomy with stent removal in people with In-Stent Carotid Artery Restenosis, run by University Hospital Ostrava at 1 site in Czechia.
Trial summary
Patients with in-stent restenosis in carotid artery indicated to carotid intervention will be randomized into repeated carotid percutaneous transluminal angioplasty with or without stenting or carotid endarterectomy with stent removal. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- In-Stent Carotid Artery Restenosis
- What is being tested?
- Carotid endarterectomy with stent removal
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteCzechia
- Study dates
- 25 May 2017to Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- In-stent restenosis in carotid artery 70 - 99 %
- Indication to carotid intervention
- Age 18-80 years
- Functionally independent with a modified Rankin score value of 0 - 2 points
- Signed Informed consent
Who cannot join
- Contraindication to general anesthesia
- Contraindication to angiography (iodine allergy, etc.)
- Technically impossible to perform angioplasty with or without stenting
- Participation in other clinical study within 60 days
- Technically impossible to perform carotid endarterectomy
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Czechia1 site, 1 recruiting
- Recruiting
University Hospital Ostrava
Ostrava, Moravian-Silesian Region, 70852
Tomas Hrbac, MD, Ph.D., +420597375402, tomas.hrbac@fno.cz
David Skoloudik, Prof MD PhD, +420597375613, skoloudik@hotmail.com
About this study
Official title: Comparison of Carotid Endarterectomy and Repeated Carotid Percutaneous Transluminal Angioplasty With or Without Stenting for In-stent Restenosis
Patients with in-stent restenosis in carotid artery indicated to carotid intervention will be randomized into repeated carotid percutaneous transluminal angioplasty with or without stenting or carotid endarterectomy with stent removal. The objective of the randomized study is to compare the safety and effectiveness of CEA and CAS in patients with in-stent restenosis of the ICA.
Read the detailed description
Patients: Patients with in-stent restenosis in carotid artery indicated to carotid intervention will be randomized into repeated carotid percutaneous transluminal angioplasty with or without stenting or carotid endarterectomy with stent removal.
Repeated carotid percutaneous transluminal angioplasty with or without stenting: Endovascular interventions are going to be performed in local anesthesia from femoral access. Unfractioned heparin (100 IU/kg bodyweight) will be administered in all patients. The procedures will start with diagnostic angiography. Upon verification of severity and morphology of the in-stent stenosis 90 cm long 6F sheath will be introduced into the CCA. The procedures will be performed using distal filter protection. In severe stenoses predilation with 3 or 4 mm diameter balloon will be carried out. In-stent restenoses will be treated preferentially with 5 mm diameter drug eluting balloon. Atropin, up to the dose of 1.0 milligram, can be administered intravenously to prevent serious bradycardia during dilation. Stent will be placed within previous stent in cases of suboptimal PTA result and the decision will be left to the discretion of the interventional specialist. Whenever possible, double-layer technology stent will be used to ensure supreme wall coverage. Distal filter will be removed followed by the completion angiogram including intracranial arteries. Dual antiplatelet therapy (clopidogrel 75 mg/day and acetylsalicylic acid 100 mg/day) will be administered for at least 6 weeks post-procedure. All patients will undergo pre-procedural laboratory testing regarding clopidogrel resistance. In poor responders clopidogrel is going to be replaced by prasugrel or ticagrelor.
Carotid endarterectomy with stent removal: Surgery will be performed in a general or a local anesthesia (decision will be left to the discretion of the operating team) using a cut in front angle of the sternomastoid muscle. Common carotid artery (CCA) and later internal carotid artery (ICA) and external carotid artery (ECA) will be cut free. Common carotid artery, ICA and ECA will be temporarily closed. Using a longitudinal cut of CCA and ICA, stent with an atherosclerotic plaque will be visualized. The stent and a plaque will be withdrawn under the microscopic control and later a suture of arteriotomy will be performed using a monofil non-absorbent fibre 6/0. Just before the end of surgery, hemostatic process will be controlled and drainage will be done. Surgery will be completed by suture of subcutis and cutis. Unfractioned heparin (100 IU/kg bodyweight) could be administered in all patients just before the arteriotomy. In the case of the insufficient collateral flow into middle cerebral artery after clipping of the CCA and ICA, a temporal shunt could be used. Antiplatelet therapy (Aggrenox, clopidogrel 75 mg/day or acetylsalicylic acid 100 mg/day) will be used continuously in all patients.
Clinical examinations: Standard physical and neurologic examinations will be performed before intervention, 24 hours and 30 days after intervention. Evaluation of the neurologic deficit will be performed using the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin scale before, 24 hours and 30 days after intervention.
Randomization: Consecutive patients will be assigned to the carotid endarterctomy with stent removal or repeated carotid percutaneous transluminal angioplasty with or without stenting by a computer-generated 1:1 randomization.
Statistical analysis: All statistical tests will be performed at the Center for Health Research, Faculty of Medicine, University of Ostrava. The normality of distribution of all proceeded data will be checked using the Shapiro-Wilk test. Data with a normal distribution will be reported as the mean ± standard deviation. Parameters not fitting a normal distribution will be presented as the mean, median and interquartile range. Categorical variables in the two arms will be compared by Fisher's exact test. Continuous variables will be compared by the Student's t-test for normally distributed values, or the Mann-Whitney U test. Spearman correlation coefficient and intraclass correlation coefficient will be calculated for the evaluation of interobserver and intraobserver agreements of brain infarction volume measurement. Multiple logistic regression analyses will be used to determine the possible predictors of stroke, TIA, retinal infarction, amaurosis fugax, myocardial infarction or vascular death. All tests will be carried out at an alpha level of significance of 0.05.
- Conditions
- In-Stent Carotid Artery Restenosis
- Being tested
- Carotid endarterectomy with stent removal
- Keywords
- endarterectomy, percutaneous transluminal angioplasty, stenting, in-stent restenosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Carotid endarterectomy with stent removalProcedure or surgery
Also called Carotid endarterectomy
Standard carotid endarterectomy will be extended with the stent removal
| Study group | Role | What they receive |
|---|---|---|
| carotid endarterectomy | Experimental | carotid endarterectomy with stent removal Receives: Procedure: Carotid endarterectomy with stent removal |
| repeated angioplasty and stenting | Active comparator | percutaneous transluminal angioplasty with or without stenting Receives: Procedure: Carotid endarterectomy with stent removal |
What is being measured
The primary outcome is the main question the study is designed to answer.
carotid stenosis
percentage of stenosis in treated carotid artery after intervention
Measured: 24 hours
Secondary outcomes (1)
vascular morbidity within 30 days
ischemic stroke, hemorrhagic stroke, myocardial infarction and/or vascular death
Measured: 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 May 2022
- Study start25 May 2017
- Primary completionDec 2026 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for In-Stent Carotid Artery RestenosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- case-control study
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital Ostrava
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Tomas Hrbac, MD, PhD, Principal investigator, University Hospital Ostrava
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05390983
- Sponsor's protocol ID
- CZ11032017
- Acronym
- CERCAS
- Status last verified
- Jan 2024
- First submitted
- 19 Apr 2022
- Last updated
- 18 Jan 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data will be available at Mendeley
Publications
Hrbac T, Fiedler J, Prochazka V, Jonszta T, Roubec M, Pakizer D, Vaclavik D, Netuka D, Heryan T, Skoloudik D. Comparison of carotid endarterectomy and repeated carotid angioplasty and stenting for in-stent restenosis (CERCAS trial): a randomised study. Stroke Vasc Neurol. 2023 Oct;8(5):399-404. doi: 10.1136/svn-2022-002075. Epub 2023 Mar 27.
PubMed 36972920
Study at a glance
From the registry record, last updated by the sponsor on 18 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Carotid Endarterectomy and Repeated Carotid Percutaneous Transluminal Angioplasty With or Without Stenting for In-stent Restenosis
- ClinicalTrials.gov ID
- NCT05390983
- Acronym / sponsor ID
- CERCAS / CZ11032017
- Conditions
- In-Stent Carotid Artery Restenosis
- Keywords
- endarterectomy, percutaneous transluminal angioplasty, stenting, in-stent restenosis
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- University Hospital OstravaUniversity, hospital or other
- Study start
- 25 May 2017 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 25 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients with in-stent restenosis in carotid artery indicated to carotid intervention will be randomized into repeated carotid percutaneous transluminal angioplasty with or without stenting or carotid endarterectomy with stent removal. The objective of the randomized study is to compare the safety and effectiveness of CEA and CAS in patients with in-stent restenosis of the ICA.
Detailed description
Patients: Patients with in-stent restenosis in carotid artery indicated to carotid intervention will be randomized into repeated carotid percutaneous transluminal angioplasty with or without stenting or carotid endarterectomy with stent removal.
Repeated carotid percutaneous transluminal angioplasty with or without stenting: Endovascular interventions are going to be performed in local anesthesia from femoral access. Unfractioned heparin (100 IU/kg bodyweight) will be administered in all patients. The procedures will start with diagnostic angiography. Upon verification of severity and morphology of the in-stent stenosis 90 cm long 6F sheath will be introduced into the CCA. The procedures will be performed using distal filter protection. In severe stenoses predilation with 3 or 4 mm diameter balloon will be carried out. In-stent restenoses will be treated preferentially with 5 mm diameter drug eluting balloon. Atropin, up to the dose of 1.0 milligram, can be administered intravenously to prevent serious bradycardia during dilation. Stent will be placed within previous stent in cases of suboptimal PTA result and the decision will be left to the discretion of the interventional specialist. Whenever possible, double-layer technology stent will be used to ensure supreme wall coverage. Distal filter will be removed followed by the completion angiogram including intracranial arteries. Dual antiplatelet therapy (clopidogrel 75 mg/day and acetylsalicylic acid 100 mg/day) will be administered for at least 6 weeks post-procedure. All patients will undergo pre-procedural laboratory testing regarding clopidogrel resistance. In poor responders clopidogrel is going to be replaced by prasugrel or ticagrelor.
Carotid endarterectomy with stent removal: Surgery will be performed in a general or a local anesthesia (decision will be left to the discretion of the operating team) using a cut in front angle of the sternomastoid muscle. Common carotid artery (CCA) and later internal carotid artery (ICA) and external carotid artery (ECA) will be cut free. Common carotid artery, ICA and ECA will be temporarily closed. Using a longitudinal cut of CCA and ICA, stent with an atherosclerotic plaque will be visualized. The stent and a plaque will be withdrawn under the microscopic control and later a suture of arteriotomy will be performed using a monofil non-absorbent fibre 6/0. Just before the end of surgery, hemostatic process will be controlled and drainage will be done. Surgery will be completed by suture of subcutis and cutis. Unfractioned heparin (100 IU/kg bodyweight) could be administered in all patients just before the arteriotomy. In the case of the insufficient collateral flow into middle cerebral artery after clipping of the CCA and ICA, a temporal shunt could be used. Antiplatelet therapy (Aggrenox, clopidogrel 75 mg/day or acetylsalicylic acid 100 mg/day) will be used continuously in all patients.
Clinical examinations: Standard physical and neurologic examinations will be performed before intervention, 24 hours and 30 days after intervention. Evaluation of the neurologic deficit will be performed using the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin scale before, 24 hours and 30 days after intervention.
Randomization: Consecutive patients will be assigned to the carotid endarterctomy with stent removal or repeated carotid percutaneous transluminal angioplasty with or without stenting by a computer-generated 1:1 randomization.
Statistical analysis: All statistical tests will be performed at the Center for Health Research, Faculty of Medicine, University of Ostrava. The normality of distribution of all proceeded data will be checked using the Shapiro-Wilk test. Data with a normal distribution will be reported as the mean ± standard deviation. Parameters not fitting a normal distribution will be presented as the mean, median and interquartile range. Categorical variables in the two arms will be compared by Fisher's exact test. Continuous variables will be compared by the Student's t-test for normally distributed values, or the Mann-Whitney U test. Spearman correlation coefficient and intraclass correlation coefficient will be calculated for the evaluation of interobserver and intraobserver agreements of brain infarction volume measurement. Multiple logistic regression analyses will be used to determine the possible predictors of stroke, TIA, retinal infarction, amaurosis fugax, myocardial infarction or vascular death. All tests will be carried out at an alpha level of significance of 0.05.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- case-control study
| Arm | Type | Receives |
|---|---|---|
| carotid endarterectomy | Experimental | Procedure: Carotid endarterectomy with stent removalcarotid endarterectomy with stent removal |
| repeated angioplasty and stenting | Active comparator | Procedure: Carotid endarterectomy with stent removalpercutaneous transluminal angioplasty with or without stenting |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- In-stent restenosis in carotid artery 70 - 99 %
- Indication to carotid intervention
- Age 18-80 years
- Functionally independent with a modified Rankin score value of 0 - 2 points
- Signed Informed consent
Key exclusion criteria (5 listed)
- Contraindication to general anesthesia
- Contraindication to angiography (iodine allergy, etc.)
- Technically impossible to perform angioplasty with or without stenting
- Participation in other clinical study within 60 days
- Technically impossible to perform carotid endarterectomy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Carotid endarterectomy with stent removalAlso: Carotid endarterectomyStandard carotid endarterectomy will be extended with the stent removal | Procedure or surgery | carotid endarterectomy, repeated angioplasty and stenting |
Primary outcome
carotid stenosis
Time frame: 24 hours
percentage of stenosis in treated carotid artery after intervention
1 secondary outcome
vascular morbidity within 30 days
Time frame: 30 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jan 2024.
- Derived from this study: PubMed 36972920Hrbac T, Fiedler J, Prochazka V, Jonszta T, Roubec M, Pakizer D, Vaclavik D, Netuka D, Heryan T, Skoloudik D. Comparison of carotid endarterectomy and repeated carotid angioplasty and stenting for in-stent restenosis (CERCAS trial): a randomised study. Stroke Vasc Neurol. 2023 Oct;8(5):399-404. doi: 10.1136/svn-2022-002075. Epub 2023 Mar 27.
- Individual participant dataSharing planned: No. Data will be available at Mendeley
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Tomas Hrbac, MD, PhD principal investigator
University Hospital Ostrava
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Carotid endarterectomy with stent removal in people with In-Stent Carotid Artery Restenosis, run by University Hospital Ostrava at 1 site in Czechia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tomas Hrbac, MD, PhD (+420597375402, tomas.hrbac@fno.cz), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
carotid stenosis (time frame: 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05390983, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jan 2024.